We are committed to the development and commercialization of first-in-class treatment options to improve the lives of patients and caregivers.
Ironshore's mission is to commercialize innovative, patient-focused treatment options to improve the lives of patients and caregivers.
Learn more about our proprietary, oral controlled-release technology for evening dosing of medication with delayed- and extended-release characteristics.
Our proprietary technologies enable precision targeting of medication to address a significant unmet medical need.
Interested in learning more about partnership opportunities with Ironshore? Use the links below to access details on our Investigator Initiated Trial (IIT) program, global patent footprint, publications and more
© 2024 Ironshore Pharmaceuticals, Inc. | PRO-CORP-3389-v1 05/24 | Site Design: Digital Elevator
Ironshore Therapeutics has been acquired by Collegium Pharmaceutical, Inc.
(Nasdaq: COLL)